$81 Million

Dynavax Technologies Corp

Follow-on Offering

Lead Left Bookrunner, May 2020

Dynavax Technologies Corp

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel vaccines. Dynavax’s sole marketed product, HEPLISAV-B, was approved in November 2017 and launched in February 2018 for the prevention of infection caused by all known subtypes of Hepatitis B virus in adults age 18 years or older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships, including efforts in support of a potential COVID-19 vaccine by the Company and its collaborators.